In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Pfizer (PFE – Research Report), with a ...

The stock's fall snapped a two-day winning streak.

Pfizer Inc. closed $4.65 short of its 52-week high ($31.54), which the company reached on July 30th.

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced an expansion of their partnership with ...

Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Company (MRK – Research Report) today and set a price target of ...

Pfizer stock (NYSE: PFE) was up 5% on Tuesday, December 17, after the company announced an optimistic outlook for 2025. The company expects its revenue to be in the range of $61 billion to $64 ...

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

Pfizer projects strong revenue and earnings for 2024 and 2025, with cost-cutting measures aiding financial growth.

Both in their mid-twenties, the two men set up what was initially a fine chemicals business in a Brooklyn factory, using a loan from Pfizer’s father as capital. The company’s first product ...

Dec 30 (Reuters) - Sangamo Therapeutics (SGMO.O), opens new tab said on Monday that partner Pfizer (PFE.N), opens new tab has terminated their hemophilia A gene therapy co-development agreement ...

"Federal law requires defendants to ensure that their drug labels remain accurate, and when new scientific information ...

Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Bank of Americ ...